Jefferies Financial Group Research Analysts Lower Earnings Estimates for Supernus Pharmaceuticals Inc (SUPN)

Supernus Pharmaceuticals Inc (NASDAQ:SUPN) – Stock analysts at Jefferies Financial Group reduced their FY2019 earnings estimates for Supernus Pharmaceuticals in a research report issued on Wednesday, November 7th. Jefferies Financial Group analyst D. Steinberg now forecasts that the specialty pharmaceutical company will post earnings of $2.50 per share for the year, down from their prior estimate of $2.52. Jefferies Financial Group has a “Buy” rating and a $58.00 price target on the stock. Jefferies Financial Group also issued estimates for Supernus Pharmaceuticals’ FY2020 earnings at $3.11 EPS, FY2021 earnings at $4.15 EPS and FY2022 earnings at $5.38 EPS.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings results on Tuesday, November 6th. The specialty pharmaceutical company reported $0.52 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.43 by $0.09. The company had revenue of $102.99 million for the quarter, compared to analyst estimates of $100.75 million. Supernus Pharmaceuticals had a net margin of 25.89% and a return on equity of 32.22%. Supernus Pharmaceuticals’s revenue for the quarter was up 28.1% on a year-over-year basis. During the same quarter last year, the business earned $0.29 EPS.

Other equities analysts have also issued research reports about the stock. BidaskClub upgraded shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Wednesday, September 12th. Zacks Investment Research upgraded shares of Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Thursday. Cantor Fitzgerald reiterated a “buy” rating and issued a $56.00 price target on shares of Supernus Pharmaceuticals in a report on Friday, September 14th. Piper Jaffray Companies reiterated a “hold” rating and issued a $46.00 price target on shares of Supernus Pharmaceuticals in a report on Wednesday, July 25th. Finally, ValuEngine lowered shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday. Four equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Supernus Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $54.78.

Shares of SUPN traded down $0.09 during mid-day trading on Friday, reaching $45.47. The company had a trading volume of 943 shares, compared to its average volume of 587,493. The firm has a market cap of $2.17 billion, a PE ratio of 36.25 and a beta of 0.92. Supernus Pharmaceuticals has a fifty-two week low of $34.90 and a fifty-two week high of $61.25. The company has a quick ratio of 2.54, a current ratio of 2.74 and a debt-to-equity ratio of 0.82.

Several hedge funds have recently modified their holdings of SUPN. Legal & General Group Plc raised its stake in shares of Supernus Pharmaceuticals by 3.1% in the 1st quarter. Legal & General Group Plc now owns 104,580 shares of the specialty pharmaceutical company’s stock valued at $4,791,000 after acquiring an additional 3,120 shares during the period. Principal Financial Group Inc. raised its stake in shares of Supernus Pharmaceuticals by 3.2% in the 1st quarter. Principal Financial Group Inc. now owns 423,062 shares of the specialty pharmaceutical company’s stock valued at $19,376,000 after acquiring an additional 13,238 shares during the period. Allianz Asset Management GmbH increased its stake in Supernus Pharmaceuticals by 60.3% during the 1st quarter. Allianz Asset Management GmbH now owns 278,701 shares of the specialty pharmaceutical company’s stock worth $12,765,000 after buying an additional 104,829 shares during the period. Bank of Montreal Can increased its stake in Supernus Pharmaceuticals by 111.5% during the 2nd quarter. Bank of Montreal Can now owns 79,922 shares of the specialty pharmaceutical company’s stock worth $4,783,000 after buying an additional 42,138 shares during the period. Finally, Scout Investments Inc. increased its stake in Supernus Pharmaceuticals by 233.6% during the 2nd quarter. Scout Investments Inc. now owns 595,096 shares of the specialty pharmaceutical company’s stock worth $35,617,000 after buying an additional 416,696 shares during the period. 99.10% of the stock is currently owned by institutional investors and hedge funds.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy.

Read More: Why Dividend Stocks May Be Right for You

Earnings History and Estimates for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply